Drugs Controller General of India (DCGI) has given approval to Natco Pharma for its generic daclatasvir dihydrochloride tablets (30 mg & 60 mg) for the treatment of hepatitis C. Daclatasvir is the NS5A inhibitor used in combination with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat hepatitis C virus patient subsets.
Natco will market generic daclatasvir under its own brand Natdac, and through its strategic partners in India. The company will launch the tablets for the 60 mg and 30 mg strengths in a bottle of 28 tablets.
Natco will market generic daclatasvir under its own brand Natdac, and through its strategic partners in India. The company will launch the tablets for the 60 mg and 30 mg strengths in a bottle of 28 tablets.